Figure 7From: Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells Evaluation of mitoxantrone and mithramycin in additional malignant lines. (a) BXPC-3, and (b) MIAPaCa2 human pancreatic cancer cells. Single-agent treatments are shown as "dark grey diamonds" and combination treatments with 10 ng/mL of TRAIL are shown as "light grey squares". Asterisks (*) and (**) indicate p-values < 0.05 and < 0.01, respectively. Data are presented on a logarithmic scale and the lines connecting data points are for visualization only.Back to article page